Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in Sweden

References

• Leal J, Luengo-Fernandez R, Gray A, et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006;27:1610-19
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. The Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Law M, Wald N, Rudnicka A. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-31
   PubMed Web of Science ®Google Scholar
• Svilaas A, Strandberg T, Eriksson M, et al. Lipid lowering patterns and goal attainment in Nordic patients with hyperlipidemia. Scand Cardiovasc J 2008;42:279-87
   PubMed Web of Science ®Google Scholar
• Lindgren P, Borgström F, Stålhammar J, et al. Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice. Eur J Cardiov Prev R 2005;12:530-4
   PubMed Web of Science ®Google Scholar
• Carlsson A, Borgström F, Stålhammar J, et al. Cost of care for patients treated with lipid-lowering drugs. Pharmacoeconomics 2004;22(Suppl. 3):25-35
   PubMedGoogle Scholar
• Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical prevention. Eur J Cardiov Prev R 2007;14(Suppl. 2):S1-113
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152-60
   PubMed Web of Science ®Google Scholar
• Peura P, Martikainen J, Soini E, et al. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Curr Med Res Opin 2008;24:1825-34
   Web of Science ®Google Scholar
• Lindgren P, Buxton M, Kahan T, et al. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial – lipid-lowering arm (ASCOT-LLA). Eur J Cardiov Prev R 2005;12:29-36
   PubMed Web of Science ®Google Scholar
• Johannesson M, Jönsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 1997;336:332-6
   PubMed Web of Science ®Google Scholar
• Benner J, Smith T, Klingman D, et al. Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective. Value Health 2005;8:618-28
   PubMed Web of Science ®Google Scholar
• Palmer S, Brady A, Ratcliffe A. The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS. Int J Clin Pract 2003;57:792-800
   PubMed Web of Science ®Google Scholar
• Peura P, Martikainen J, Hallinen T, et al. Statiinien teho ja kustannusvaikuttavuus [Cost-effectiveness of statins in reaching LDL cholesterol levels defined in Current Care Guidelines]. Fin Med J 2007;42:3899-905
   Google Scholar
• Läkemedelsförmånsnämnden (LFN). Price database (pharmaceuticals), 2008
   Google Scholar
• Södra Regionvårdsnämnden. Regionala priser och ersättningar för södra sjukvårdsregionen 2008 [http://www.skane.se/upload/Webbplatser/Sodra%20regionvardsnamnden/prislista/2008/helaprislistan2008.pdf. Last accessed 7 December 2007]
   Google Scholar
• Law MR, Wald N, Thompson S. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?. BMJ 1994;308:367-72
   PubMed Web of Science ®Google Scholar
• Jowett S, Stirling B, Mahé I, et al. A multinational investigation of time and traveling costs in attending anticoagulation clinics. Value Health 2008;11:207-11
   PubMed Web of Science ®Google Scholar
• Werner P, Brun J. POST (Prescription of statin study) – en model för kvalitetsuppföljning av lipidsänkande läkemedel i sjukvården. Medicinskt Forum 2006;2:22-5
   Google Scholar
• Briggs A, Goeree R, Blackhouse G, et al. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002;22:290-308
   PubMed Web of Science ®Google Scholar
• Drummond M, Sculpher M, Torrance G, et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd Edn. New York: Oxford University Press, 2005
   Google Scholar
• Barton G, Briggs A, Fenwick E. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curves (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfect information (EVPI). Value Health 2008;11:886-97
   PubMed Web of Science ®Google Scholar
• American Diabetes Association (ADA).Standards of medical care in diabetes. Diabetes Care 2005;28:S4-36
   PubMed Web of Science ®Google Scholar
• Silva M, Swanson A, Gandhi P, et al. Statin-related adverse events: a meta-analysis. Clin Ther 2006;28:26-35
   PubMed Web of Science ®Google Scholar
• Heintjes E, Hirsch M, van der Linden M, et al. LDL-C reductions and goal attainment among naïve statin users in the Netherlands: real life results. Curr Med Res Opin 2008;8:2241-50
   Google Scholar